Urocortin 3 gene therapy can increase systolic and diastolic function in heart failure, reveals a new study.

TOP INSIGHT
Urocortin 3 gene therapy increases systolic and diastolic function in heart failure.
Read More..
The article entitled "Urocortin 3 Gene Transfer Increases Function of the Failing Murine Heart," was coauthored by H. Kirk Hammond, Veterans Affairs (VA) San Diego Healthcare System and University of California, San Diego and a team of researchers from those institutions, Maastricht University, The Netherlands, and Institute for Molecular Cardiovascular Research, RWTH, Aachen, Germany.
The researchers presented data to support the sustained elevation of plasma UCn3 levels and significantly improved left ventricular function (1.9 fold) and higher ejection fractions (32% relative increase) compared to mice who received a saline injection after cryoinjury.
"The outstanding group from the San Diego VA led by Dr. Hammond has continued to pioneer new viable gene therapy options for the extremely common problem of congestive heart failure," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA.
Research reported in this publication was supported by the National Institutes of Health under Award Number P01 HL66941. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
MEDINDIA




Email










